7.5 DEVELOPMENT FUNDS Developmental Funds comprise one of the most important tools the Arizona Cancer Center director has to enhance the Center and to meet future goals and initiatives. Throughout its history, the AZCC has used the funds to recruit and support new investigators during their start-up years, to finance pilot projects by promising young researchers, to initiate new programs and develop new services that support the peerreviewed research, and to provide interim funding to researchers who show promise of obtaining renewed funding. Accordingly, the developmental funds have proven to be highly productive and have been returned many-fold in the form of follow-up peer-reviewed funding for investigators and in the fonn of scientific contributions in cancer research. In the past cycle, funds have been used to fund new investigators, support pilot projects, provide interim funding to investigators and to develop new services in our shared services such as tissue collection for our TACMA shared service, mythelation methodologies for our Genomics shared service, genetically engineered mouse models for our Experimental Mice shared service, and the development of web-based applications for our Behavioral Measurement shared service. This proposal describes the effective use of the funds and plans for future development. Annual support is request in the amount of $375,000.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-35
Application #
8540921
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
35
Fiscal Year
2013
Total Cost
$447,099
Indirect Cost
$152,343
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Dickinson, Sally E; Janda, Jaroslav; Criswell, Jane et al. (2016) Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Cancer Prev Res (Phila) 9:215-24
Schissler, A Grant; Li, Qike; Chen, James L et al. (2016) Analysis of aggregated cell-cell statistical distances within pathways unveils therapeutic-resistance mechanisms in circulating tumor cells. Bioinformatics 32:i80-i89
Banerjee, Bhaskar; Shaheen, Nicholas J; Martinez, Jessica A et al. (2016) Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients. Cancer Prev Res (Phila) 9:528-33
Pulko, Vesna; Davies, John S; Martinez, Carmine et al. (2016) Human memory T cells with a naive phenotype accumulate with aging and respond to persistent viruses. Nat Immunol 17:966-75
Warfel, Noel A; Sainz, Alva G; Song, Jin H et al. (2016) PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther 15:1637-47
Thomson, Cynthia A; Ho, Emily; Strom, Meghan B (2016) Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutr Rev 74:432-43
Tsikitis, Vassiliki L; Potter, Amiee; Mori, Motomi et al. (2016) MicroRNA Signatures of Colonic Polyps on Screening and Histology. Cancer Prev Res (Phila) 9:942-949
Hanke, Neale T; Garland, Linda L; Baker, Amanda F (2016) Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol 142:549-60
Kohler, Lindsay N; Garcia, David O; Harris, Robin B et al. (2016) Adherence to Diet and Physical Activity Cancer Prevention Guidelines and Cancer Outcomes: A Systematic Review. Cancer Epidemiol Biomarkers Prev 25:1018-28
Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35

Showing the most recent 10 out of 1161 publications